Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage Therapeutics
Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage Therapeutics
PR Newswire
MILWAUKEE, March 7, 2024
MILWAUKEE, March 7, 2024 /PRNewswire/ -- Ademi LLP is investigating BiomX (NYSE American: PHGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Adaptive Phage Therapeutics.
Click here to learn how to join the https://www.ademilaw.com/case/biomx-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, BiomX will issue 9,164,967 shares of BiomX common stock, 40,471 shares of Series X Preferred Stock convertible into 40,471,000 shares of BiomX common stock and warrants exercisable for 2,166,497 shares of BiomX common stock.
We are investigating the conduct of BiomX's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own BiomX common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/biomx-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-the-transaction-between-biomx-inc-and-adaptive-phage-therapeutics-302082480.html
SOURCE Ademi LLP
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending